{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:46:24Z","timestamp":1790721984655,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.annonc.2023.10.121","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:40:05Z","timestamp":1698446405000},"page":"130-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-4564","authenticated-orcid":false,"given":"A.S.","family":"Cottereau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-8732","authenticated-orcid":false,"given":"L.","family":"Rebaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.W.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Portugues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Buvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.annonc.2023.10.121_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2023.10.121_bib2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2023.10.121_bib3","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2023.10.121_bib4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1127","key":"10.1016\/j.annonc.2023.10.121_bib5","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma - an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"Br J Radiol"},{"issue":"21","key":"10.1016\/j.annonc.2023.10.121_bib6","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2023.10.121_bib7","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1182\/bloodadvances.2021006923","article-title":"A\u00a0tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma","volume":"6","author":"Thieblemont","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.annonc.2023.10.121_bib8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.annonc.2023.10.121_bib9","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.annonc.2023.10.121_bib10","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.4143\/crt.2018.649","article-title":"Prognostic value of baseline and interim total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT in patients with follicular lymphoma","volume":"51","author":"Liang","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.annonc.2023.10.121_bib11","article-title":"Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET\/CT","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2023.10.121_bib12","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-derived metabolic tumor volume metrics did not predict outcomes in follicular lymphoma patients treated with first-line immunochemotherapy and antibody maintenance in the phase III GALLIUM study","volume":"132","author":"Barrington","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2023.10.121_bib13","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2019-124793","article-title":"A\u00a0fully automated measurement of total metabolic tumor burden in diffuse large B-cell lymphoma and follicular lymphoma","volume":"134","author":"Jemaa","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.annonc.2023.10.121_bib14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2023.10.121_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.annonc.2023.10.121_bib16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"28","key":"10.1016\/j.annonc.2023.10.121_bib17","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab (R(2)) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2023.10.121_bib18","first-page":"3857","article-title":"Improving the prognostic ability of PET\/CT SUVmax to identify follicular lymphoma with early treatment failure","volume":"12","author":"Wan","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2023.10.121_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.annonc.2023.10.121_bib20","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2023.10.121_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A\u00a0gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.10.121_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106980","article-title":"Development of a new risk scoring system based on spleen involvement and the lymphocyte\/monocyte ratio for follicular lymphoma patients","volume":"123","author":"Li","year":"2022","journal-title":"Leuk Res"},{"issue":"31","key":"10.1016\/j.annonc.2023.10.121_bib23","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study","volume":"37","author":"Bachy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2023.10.121_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140830","article-title":"Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline 18FFDG PET to predict survival in Hodgkin lymphoma","volume":"10","author":"Kanoun","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.annonc.2023.10.121_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2967\/jnumed.116.180406","article-title":"Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma","volume":"58","author":"Cottereau","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.annonc.2023.10.121_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00259-018-4200-3","article-title":"Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?","volume":"46","author":"Ilyas","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.annonc.2023.10.121_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2020.263194","article-title":"Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.annonc.2023.10.121_bib28","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.annonc.2023.10.121_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.annonc.2023.10.121_bib30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(dagger)","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2023.10.121_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.3025","article-title":"Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interim PET-negative classical Hodgkin Lymphoma patients: a radio-genomic study","volume":"40","author":"Durmo","year":"2022","journal-title":"Hematol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423043272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423043272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:12:55Z","timestamp":1762319575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423043272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0923753423043272"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.121","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}